Our examination revealed a consistent downregulation of LINC-PINT across seven distinct tumor types, namely Bladder Urothelial Carcinoma (BLCA), Breast Invasive Carcinoma (BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Glioblastoma Multiforme (GBM), Lung Squamous Cell Carcinoma (LUSC), Thyroid Carcinoma (THCA), and Uterine Corpus Endometrial Carcinoma (UCEC). This evidence concerns the gene LINC-PINT and invasive breast carcinoma.